SiRNA for treating hepatic fibrosis and delivery preparation thereof

A preparation, small interference technology, applied in the direction of DNA/RNA fragments, recombinant DNA technology, medical preparations with non-active ingredients, etc., can solve problems such as adverse reactions, and achieve the effect of reducing expression level and good delivery effect.

Pending Publication Date: 2021-03-19
YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional drugs may have adverse reactions caused by factors such as large doses, and gene therapy has become an indispensable research direction for future anti-hepatic fibrosis due to its high efficiency, strong targeting, and easy operation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • SiRNA for treating hepatic fibrosis and delivery preparation thereof
  • SiRNA for treating hepatic fibrosis and delivery preparation thereof
  • SiRNA for treating hepatic fibrosis and delivery preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Effect of NOX1 siRNA 1 on carbon tetrachloride-induced acute liver injury in mice, and comparison with positive drug silibinin

[0036] Reagents and Instruments

[0037] CCL4 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., article number: C112040, batch: B2027005), soybean oil (Arowana, Q / BBAH0019S), Nox1 siRNA1 (synthesized by Suzhou Beixin Biotechnology Co., Ltd., and the sense chain nucleus Nucleotide sequence: 5'-GAGAUGUGGGAUGAUCGUGACTT-3', antisense strand nucleotide sequence: 5'-GUCACGAUCAUCCCACAUCUCTT-3'), silibinin (purchased from Dalian Meilun Biotechnology Co., Ltd., item number: MB1962, batch : 00801A), CMC-Na (purchased from Beijing Suo Laibao Technology Co., Ltd., article number: C8620, batch: 617O022), in vivo-jetPEI (Polyplus Company of France), paraformaldehyde, liver tissue RNA extraction kit, reverse Transcription Kit.

[0038] experimental method

[0039] There were 56 male C57BL / 6 mice (Victoria), and the weight of th...

Embodiment 2

[0068] Example 2: Effect of NOX1 siRNA 2 on carbon tetrachloride-induced acute liver injury in mice, and comparison with the positive drug silibinin

[0069] Except that the RNA used was Nox1 siRNA 2 (entrusted to Suzhou Beixin Biotechnology Co., Ltd. to synthesize, the sense strand nucleotide sequence: 5'-CAAGCUGGUGGCCUAUAUGAUTT-3', the antisense strand nucleotide sequence: 5'-AUCAUAUAGGCCACCAGCUUGTT-3' ), other operations are the same as in Example 1.

[0070] Obtaining test effect data is equivalent to embodiment 1.

Embodiment 3

[0071] Example 3: Effect of NOX1 siRNA 2 on carbon tetrachloride-induced chronic liver fibrosis model in mice, and comparison with the positive drug silibinin

[0072] Reagents and Instruments

[0073]CCL4 (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., article number: C112040, batch: B2027005), soybean oil (Arowana, Q / BBAH0019S), Nox1 siRNA 2 (synthesized by Suzhou Beixin Biotechnology Co., Ltd., nucleic acid sequence : 5'-CAAGCUGGUGGCCUAUAUGAUTT-3', antisense nucleic acid sequence: 5'-AUCAUAUAGGCCACCAGCUUGTT-3'), silibinin (purchased from Dalian Meilun Biotechnology Co., Ltd., item number: MB1962, batch: 00801A), CMC- Na (purchased from Beijing Suolaibao Technology Co., Ltd., article number: C8620, batch: 617O022), in vivo-jetPEI, paraformaldehyde, liver tissue RNA extraction kit, reverse transcription kit, intragastric injection needle, syringe, Surgical instruments, inverted microscope, real-time fluorescent quantitative PCR instrument, PCR instrument, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a small interfering RNA. The small interfering RNA performs RNA interference (RNAi) through NOX1 siRNA, and can effectively target NOX1 protein, inhibit the generation of reactive oxygen species (ROS), and effectively inhibit the activation of hepatic stellate cells (HSC) so as to treat hepatic fibrosis.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an siRNA for treating liver fibrosis and a delivery preparation thereof. Background technique [0002] RNA interference (RNA interference, abbreviated as RNAi) refers to a gene silencing phenomenon induced by double-stranded RNA in molecular biology, and its mechanism is to inhibit gene expression by hindering the transcription or translation of specific genes. When double-stranded RNA homologous to the coding region of endogenous mRNA is introduced into cells, the mRNA is degraded and gene expression is silenced. siRNA (Small interfering RNA, small interfering nucleic acid) with a length of 20-25nt can trigger RNAi, can specifically down-regulate or close the expression of specific genes, and has the characteristics of high efficiency, easy synthesis and easy operation, so this technology has been Widely used in the field of gene therapy for exploring gene function an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/113A61K31/713A61K9/08A61K47/34A61P1/16
CPCC12N15/1137A61K31/713A61K9/08A61K9/0019A61K47/34A61P1/16C12N2310/141A61P11/00
Inventor 崔文浩赵成江王猛郑智田欢栋
Owner YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap